Press Releases

Press Releases

January 2, 2020
Patients treated with AKCEA-APO(a)-L Rx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway BOSTON and CARLSBAD, Calif. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc.
December 18, 2019
Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 BOSTON and CARLSBAD, Calif. , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc.
December 16, 2019
Lynne Parshall appointed chair and Barbara Yanni joins as new member of the Akcea board BOSTON , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , today announced the appointments of Lynne Parshall , J.D., as chair
December 4, 2019
Alex Howarth joins Akcea from Lycera, bringing more than 25 years of experience in the biopharmaceutical sector BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
November 25, 2019
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical trial for
November 19, 2019
BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the closing of the exclusive licensing agreement with Pfizer Inc.
November 13, 2019
BOSTON , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company
November 5, 2019
Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA ® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-L Rx Conference Call Webcast Tuesday, November 5 , 4:30 p.m. ET at  www.akceatx.com BOSTON , Nov.
November 1, 2019
Approval and launch of WAYLIVRA® (volanesorsen) in Europe, the only treatment option for FCS patients, highlights progress in clinical research BOSTON , Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
October 23, 2019
Kyle Jenne promoted from previous role as U.S. commercial lead to support continued strategic expansion of global commercial operations BOSTON , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc.